Xu Zhijie, Peng Bi, Cai Yuan, Wu Geting, Huang Jinzhou, Gao Ming, Guo Guijie, Zeng Shuangshuang, Gong Zhicheng, Yan Yuanliang
Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Biochem Pharmacol. 2020 Dec;182:114258. doi: 10.1016/j.bcp.2020.114258. Epub 2020 Oct 2.
Several strategies, including chemotherapy and radiotherapy, have improved therapeutic outcomes among cancer patients in clinical practice. However, due to their heterogeneity, cancer cells frequently display primary or acquired therapeutic resistance, thereby resulting in treatment failure. The mechanisms underlying cancer therapeutic resistance are complex and varied. Among them, N6-methyladenosine (m6A) RNA modification has gained increasing attention as a potential determinant of therapy resistance within various cancers. In this review, we primarily describe evidence for the effect of the m6A epitranscriptome on RNA homeostasis modulation, which has been shown to alter multiple cellular pathways in cancer research and treatment. Additionally, we discuss the profiles and biological implications of m6A RNA methylation, which is undergoing intensive investigation for its effect on the control of therapeutic resistance.
包括化疗和放疗在内的多种策略已在临床实践中改善了癌症患者的治疗效果。然而，由于癌细胞的异质性，它们经常表现出原发性或获得性治疗抗性，从而导致治疗失败。癌症治疗抗性的潜在机制复杂多样。其中，N6-甲基腺苷（m6A）RNA修饰作为各种癌症中治疗抗性的潜在决定因素，受到越来越多的关注。在本综述中，我们主要描述了m6A表观转录组对RNA稳态调节作用的证据，这已被证明在癌症研究和治疗中会改变多种细胞途径。此外，我们讨论了m6A RNA甲基化的特征和生物学意义，其对治疗抗性控制的影响正在深入研究中。
